Evidence map›Paper›PMID 42411822›Full record

ArticleBriefings in bioinformatics2026

Accurate prediction of asparagine deamidation in biologics using advanced machine learning models.

Shafayat Ahmed, Nicole Swope, Valentin Stanev, Romina Hofele, Dominique WuDunn, Rohan Jain, Jared Delmar, Maryam Pouryahya

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shafayat AhmedData Science and Modelling, Biopharmaceutical Development, AstraZeneca, 1 MedImmune Way, Gaithersburg, MD 20878, United States.
Nicole SwopeAnalytical Sciences, Biopharmaceutical Development, AstraZeneca, 1 MedImmune Way, Gaithersburg, MD 20878, United States.
Valentin StanevData Science and Modelling, Biopharmaceutical Development, AstraZeneca, 1 MedImmune Way, Gaithersburg, MD 20878, United States.
Romina HofeleAnalytical Sciences, Biopharmaceutical Development, AstraZeneca, 1 MedImmune Way, Gaithersburg, MD 20878, United States.
Dominique WuDunnAnalytical Sciences, Biopharmaceutical Development, AstraZeneca, 1 MedImmune Way, Gaithersburg, MD 20878, United States.
Rohan JainData Science and Modelling, Biopharmaceutical Development, AstraZeneca, 1 MedImmune Way, Gaithersburg, MD 20878, United States.
Jared DelmarAnalytical Sciences, Biopharmaceutical Development, AstraZeneca, 1 MedImmune Way, Gaithersburg, MD 20878, United States.ORCID 0009-0004-2642-7253
Maryam PouryahyaData Science and Modelling, Biopharmaceutical Development, AstraZeneca, 1 MedImmune Way, Gaithersburg, MD 20878, United States.ORCID 0000-0002-0445-8364

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The spontaneous deamidation of asparagine residues remains a major obstacle to the stability and efficacy of protein therapeutics. Currently available models in the literature for predicting deamidation liabilities can suffer from limited generalizability, likely due to biases such as sequence similarity within datasets. In this study, we built machine learning models using protein language models (PLMs, e.g. ESM2) and graph neural networks (GNNs), trained on a comprehensive dataset of 591 asparagine sites from over 105 protein molecules. To address the critical issue of data leakage, we implemented a peptide grouping strategy yielding more accurate estimates of model performance for novel deamidation sites. Our analysis shows that, when sequence similarity bias is controlled, PLMs match traditional feature-based models that use amino acid composition and predicted secondary structure/solvent accessibility, while offering substantial computational advantages. Additionally, our GNN-based pipeline further increases prediction accuracy by $\sim$8% compared with language model-only tools and delivers a 15%-25% improvement over motif-based approaches. This methodological framework enables more reliable and rapid in-silico prediction of deamidation liabilities, potentially reducing costly late-stage interventions in protein therapeutic development and is generalizable to the modeling of other protein post-translational modifications.

Indexed as

AmidesAsparagineBiological ProductsMachine LearningProteinsGraph Neural NetworksPrediction AlgorithmsPredictive Learning ModelsAmidesAsparagineBiological ProductsProteinsAlphaFolddeamidationESM2fine-tuningGNNPLM

Identifiers

PMID42411822
PMCPMC13338906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.